Lancet Oncology

Article	Citations
England almost a decade behind on smokefree 2030 target	778
National crises and cancer control: challenges for Latin America and beyond	756
Strengthening cancer control in Africa gathers momentum	679
ASTRO calls for a new value-based reimbursement structure for radiotherapy	515
Improving access to surgery for childhood cancer	513
Importance of modelling for cancer management during COVID-19	490
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis	458
Pembrolizumab as adjuvant therapy in non-small-cell lung cancer	453
A new era of risk prediction for patients with high-risk melanoma	416
Alabama Supreme Court's “extrauterine children” decision alarms oncologists and fertility experts	415
Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia	406
Use of artificial intelligence to enhance detection of nodal metastases	393
Patients with cancer in Louisiana denied fertility preservation cover	383
How molecularly similar are primary and metastatic tissues in renal cell carcinoma?	366
Biden's proposed investment in cancer research sparks concerns	354
Failure to tackle workforce shortages threatens cancer survival progress in England	353
Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer	352
Cancer care in Afghanistan after the Taliban takes over	326
Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa	317
Global linear accelerator requirements and personalised country recommendations: a cross-sectional, population-based study	315
Closing the research gaps in obstetric health for survivors of cancer	303
Concerns regarding the AtTEnd trial in advanced endometrial carcinoma	299
Correction to Lancet Oncol 2024; 25: 1310–24	295
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a rando	294
Discussions on the future of cancer care at the World Economic Forum in 2025	291

UK's National Cancer Plan needs to be radical, accountable, and deliverable	287
Decentralisation to improve cancer services in DR Congo	286
Correction to Lancet Oncol 2024; 25: 1424–39	286
Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis	280
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial	272
Polygenic risk scores in cancer screening: a glass half full or half empty?	271
Adjuvant immunotherapy for renal cell carcinoma	265
Impact of health insurance type on access to vaccination and mortality due to COVID-19 on patients with cancer in Colombia: a cohort study	262
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm	261
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply	261
Gestational trophoblastic neoplasia: one size does not fit all	259
Clinical features and outcomes of NAFLD-related hepatocellular carcinoma – Authors' reply	256
2021 ASTRO annual meeting	253
Bridging the equity gap in patient education: the biliary tract cancer BABEL project	251
US Air Force to study nuclear missile base lymphomas	251
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma	250
BRCA testing launched for people of Jewish ancestry in England	245
Secondary cytoreduction for relapsed ovarian cancer	245
Modernising the US FDA's Accelerated Approval pathway	242
US radiation oncology organisations work towards Medicare payment reform	241
The GLOW trial in chronic lymphocytic leukaemia	237
Sub-Saharan Africa's harmonised cancer guidelines	233
Primary ovarian insufficiency prediction in adult survivors of childhood cancer: model concerns	228
US Surgeon General calls for cancer warning labels on alcohol	224
Texan judge blocks US FDA changes on cigarette packaging	223
Correction to Lancet Oncol 2021; 22: 1081–92	220
Cancer incidence associated with PFAS contamination of drinking water in the USA	219
Correction to Lancet Oncol 2019; 20: 1750–59	218
Correction to Lancet Oncol 2021; 22: 1061	217
COVID-19 pandemic causes cervical cancer screening crisis	216
Correction to Lancet Oncol 2019; 20: 1211–25	215
Tobacco industry influence during the COVID-19 pandemic	206
Putting patient safety first: a global imperative	202
International variation in chemotherapy use in cancers	199
Addressing oncology's contribution to climate change	199
ESTRO 2024	198
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy	196
SABR for operable stage I non-small-cell lung cancer: comparison to surgery	195
Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer – Authors' reply	195
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study	194
Risk-based lung cancer screening eligibility criteria: towards implementation	188
The CReDO workshop: a promising venture needing urgent reform	186
Sentinel nodes and breast cancer: an old story	185
Long-term versus short-term androgen deprivation combined with EBRT for unfavourable prostate cancer	182
Yale Precision Medicine Tumor Board: reawakening the guardian of the genome	178
Benefit of adjuvant, but not concurrent, temozolomide for IDH-mutant anaplastic astrocytoma	177
Early evidence for cancer in Sudan: an advanced example of bone metastases from ancient Nubia (circa 2500–2050 BCE)	175
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer	174
Alternative approaches to risk–benefit balancing in immunotherapy	170
Antibody–drug conjugates in acute myeloid leukaemia: more research needed	169

Olanzapine for chemotherapy-induced nausea and vomiting control	168
Environmental pollution and cancer risk in La Oraya, Peru	167
Expansion of radiotherapy access in Ethiopia	167
Study bolsters concerns about US FDA accelerated drug approvals	166
CALLA trial: immunotherapy in locally advanced cervical cancer	164
99mTc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplastic syndrome in metastatic breast cancer	162
Prostate ultra-radical radiotherapy: reinventing the wheel	161
Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial	161
HPV mRNA testing in cervical cancer screening	160
Brachytherapy—a dose of pragmatism needed	160
Cancer control collaborations between China and African countries	155
Consolidation in US health care negatively impacts cancer care	153
Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?	153
CAR T cells for the long run in aggressive B-cell lymphoma	152
Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer	151
Serious health-related suffering in Latin America: a secondary analysis	146
Gastric signet-ring cell adenocarcinoma masquerading as sarcoidosis	146
The UK's re-entry into the Horizon Europe programme	145
Expression of concern—Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-labe	145
Global cancer control: choosing the road less travelled	144
Commercial determinants of cancer	143
Adjuvant or neoadjuvant treatment with immune checkpoint inhibitors: re-assessing the risk–benefit ratio	143
Cancer care crisis in Nigeria amid doctors' strike	142
The challenges of inadequate financial support for Australians with cancer	141
Is complete mesocolic excision superior to conventional colectomy for colon cancer?	140
On the ROMANA 1 and 2 studies on anamorelin	139
Still waiting for a UK cancer plan that truly delivers	138
Early-stage classical Hodgkin lymphoma in children and adolescents: when can radiotherapy be safely omitted?	137
Survivorship after neoadjuvant chemotherapy	137
The ways we talk about cancer	137
18F-NaF PET–CT versus 99mTc SPECT in bone metastasis assessment	135
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies	133
IVLBCL mimicking VEXAS syndrome	133
The UK needs to be a leader, not a lagger, in the global cancer effort	133
Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the Americ	132
Theranos: the proof that public regulation matters	131
Rezvilutamide for metastatic hormone-sensitive prostate cancer	128
Surrogate endpoints in breast cancer screening trials – Authors' reply	128
Thoracic CT follow-up after non-small-cell lung cancer resection – Authors' reply	125
Targeted alpha therapy: a new tool for advanced prostate cancer	123
The future of precise cancer chronotherapeutics	123
US cancer drug prices do not reflect benefits to patients	123
2020 cancer incidence data in the USA reveal effects of the COVID-19 pandemic	123
A new generation of comprehensive precision oncology trials	122
Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study	121
Cancer detection, diagnosis, and treatment for adults with disabilities	120
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial	119
President Biden outlines plans for Cancer Moonshot 2.0	118
New evidence that air pollution contributes substantially to lung cancer	117
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial	115
Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial	113
Daytime versus evening infusions of immune checkpoint inhibitors	113
SABR for operable stage I non-small-cell lung cancer: comparison to surgery	112
The impact of the EU General Data Protection Regulation on childhood cancer research in Europe	112
Patients with head and neck cancer unfit for cisplatin—what next?	111
I'm Still Me: the many faces of cancer	110
Carolyn Taylor and Global Focus on Cancer	108
Molecular imaging targeting carbonic anhydrase 9 in clear-cell renal cell carcinoma: more than meets the eye	108
Prior authorisation is can harm patients with cancer in the USA	108
Optimising therapy and avoiding overtreatment in breast cancer	106
FNAB samples with the STRAT4 assay for breast cancer diagnosis – Authors' reply	106
Bangladesh faces serious air pollution crisis	105
Limitations of the PRODIGE 7 trial	104
Carcinogenicity of 1,1,1-trichloroethane and four other industrial chemicals	103
Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy	103
Impact of the COVID-19 pandemic on the diagnosis of cancer in Japan: an observational study of hospital-based cancer registries data	102
Artificial intelligence and cancer diagnosis: caution needed	102
Catastrophic expenditure and treatment delivery outcomes in patients with colorectal cancer in India: a prospective, multicentre cohort study	101
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges	98
New strategies for standardised and appropriate access to a complete acute lymphocytic leukaemia diagnostic panel for children in Mexico: an observational study	98
Medical treatment for active breast cancer brain metastases	96
Biomedicine and the soul of medicine: optimising the balance	96
Palliative radiotherapy for hepatic cancer pain	94
Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis	94
Secondary cytoreductive surgery with HIPEC: a promising therapeutic option for recurrent ovarian cancer	94
Evaluating drug delivery enhancement following ultrasound treatment	93
New funding for Indigenous-led cancer research and nationwide clinical trials in Australia	93
African culture, traditional medicine, and cancer care	92
Addressing the childhood cancer crisis in sub-Saharan Africa	91
Amelanotic melanoma presented as multiple flesh-coloured islands	90

First-in-patient study of OTL78 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer: a single-arm, phase 2a, feasibility trial	90
Cancer-predisposing germline variants and subsequent cancer risk	90
Combination immunotherapy in chemotherapy in gastric cancer	88
Africa reaffirms commitments to eliminate cervical cancer	88
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study	86
Ethical considerations for the modification of routine human papillomavirus immunisation schedules	86
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis	84
Patient first; person first	82
Sacral insufficiency fracture after treatment for cervical cancer	81
Pembrolizumab plus chemotherapy for advanced gastric cancer	80
Randomised trials in children with rhabdomyosarcoma: time for a change?	78
New Canadian draft breast screening guidelines issued	77
New combination therapy for thymic epithelial tumours	77
Dual therapy in metastatic castration-resistant prostate cancer	77
Bridging the gender gap in childhood cancer: a call to action	76
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries	76
Fluorescence in prostate cancer surgery	76
Cancer research funding data to drive collaboration and inform action	74
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO	74
Predicting benefit from [177Lu]Lu-PSMA-617 therapy: what do we need to know?	74
Elucidating the association between antihypertensive drugs and cancer: a need for real-world studies	74
What is the best choice of follow-up procedure following resection of lung cancer?	73
Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St	72
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer – Authors' reply	72
Effects of trauma history on cancer-related screening, diagnosis, and treatment	72
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply	72
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study	71
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life result	70
Adverse obstetric outcomes in female survivors of adolescentand young adult cancers – Authors' reply	67
Multimodality imaging of a large incidental papillary fibroelastoma	66
The UK's contribution to cancer control in low-income and middle-income countries	66
Surgery versus SABR for early-stage lung cancer—time to call it a draw?	66
Radiotherapy with genomic-adjusted radiation dose – Authors' reply	65
ICGC-ARGO precision medicine: familial matters in pancreatic cancer	65
CONFIRMing single-drug immune checkpoint blockade efficacy in mesothelioma	65
Streamlining the WHO cervical cancer elimination goal	65
Cancer care for displaced children in Lebanon	65
Radiographic progression-free survival in the ACIS trial for prostate cancer – Authors' reply	64
USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study	64
Association of the interaction between mosaic chromosomal alterations and polygenic risk score with the risk of lung cancer: an array-based case-control association and prospective cohort study	64
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview	63
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer	63
Should chemoradiotherapy be standard to maximise cure in localised gastro-oesophageal cancer?	63
Italy to pass law on the right to be forgotten for cancer survivors	62
New immigration laws could undermine cancer research in the UK	61
Endoscopic surveillance in hereditary diffuse gastric cancer – Authors’ reply	61
Disappointment facing patients with breast cancer as trastuzumab deruxtecan too expensive for NHS	60
Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer	59
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEY	59
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open	59
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	59
Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era	58
Anticipating the COVID-19-related surge in cancer care demand is urgent in Latin America and the Caribbean	58
Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study	57
Correction to Lancet Oncol 2024; 25: e374–87	56
Correction to Lancet Oncol 2022; 23: 1133–44	56
Correction to Lancet Oncol 2021; 22: 1468–82	56
Correction to Lancet Oncol 2023; 24: 1042–52	56
Correction to Lancet Oncol 2021; 22: 74–84	56
Correction to Lancet Oncol 2021; 22: 309–20	56
Correction to Lancet Oncol 2022; 23: e374–84	55
Correction to Lancet Oncol 2021; 22: 1518–29	55
Correction to Lancet Oncol 2022; 23: 1124–26	55
Correction to Lancet Oncol 2022; 23: e469–78	54
How can we achieve equitable global access to cancer imaging and care?	54
Correction to Lancet Oncol 2020; 21: 671–84	54
Correction to Lancet Oncol 2023; published online July 27. https://doi.org/10.1016/S1470-2045(23)00381-9	54
The Great Secret: chemotherapy's fiery birth	53
Anti-ableist oncology care: ensuring equity for people with physical disabilities	53
Nuclear medicine theranostics comes of age	53
Correction to Lancet Oncol 2022; 23: 950–60	53
US FDA proposes stronger laboratory test oversight	52
Lessons and opportunities from improved understanding of global lung cancer histological subtypes	52
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia	51
Correction to Lancet Oncol 2020; 21: 1465–77	51
UK and France form partnership to tackle greatest challenges in cancer	51
The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research	50
COVID-19 mRNA vaccine-related adenopathy mimicking metastatic melanoma	50
Call for actions to address hepatocellular carcinoma in sub-Saharan Africa	50
Innovation in gynaecological cancer: highlighting global disparities	50
Correction to Lancet Oncol 2022; 23: 990	50
New junk food legislation in Colombia	49
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study	49
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial	49
Burden of cancer in adolescents and young adults	48
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled,	48
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019	48
The silent malignant mesothelioma epidemic: a call to action	48
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium	47
Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1	47
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi	47
Conflict in Ukraine and its impact on cancer care	47
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study	46
Health service planning to assess the expected impact of centralising specialist cancer services on travel times, equity, and outcomes: a national population-based modelling study	46
The challenge of improving outcomes in locally advanced cervical cancer	46